Physician profile
Ryan M Casper
NPI 1306898846
$19,707.15
in general payments reported to CMS, 2019-2025
44 companies · $4,036 in 2025
The $4,036 reported for 2025 was more than what 81% of Allergy & Immunology providers received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,237 · 2020: $943 · 2021: $2,426 · 2022: $2,893 · 2023: $3,308 · 2024: $3,865 · 2025: $4,036.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $11K · Consulting Fee: $246 · Education: $78.53.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $10,883.77 |
| Consulting Fee | $246.35 |
| Education | $78.53 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $2,431.02 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Csl Behring | $2,325.64 | 2019-2025 | Hizentra, Haegarda, Andembry |
| Astrazeneca Pharmaceuticals Lp | $1,844.51 | 2019-2025 | Fasenra, Tezspire, Airsupra |
| Genzyme Corporation | $1,718.81 | 2019-2025 | |
| Pfizer INC. | $1,166.21 | 2019-2025 | |
| Grifols USA, LLC | $1,068.99 | 2019-2025 | Xembify, Prolastin-C Liquid |
| Regeneron Healthcare Solutions, INC. | $1,041.22 | 2019-2025 | Dupixent |
| Takeda Pharmaceuticals U.S.A., INC. | $1,009.68 | 2020-2025 | Cuvitru, Eohilia, Hyqvia |
| Novartis Pharmaceuticals Corporation | $780.52 | 2019-2025 | |
| Optinose US, INC. | $761.09 | 2019-2025 | |
| Genentech USA, INC. | $750.33 | 2019-2025 | Xolair |
| Octapharma USA, INC. | $459.01 | 2019-2025 | Panzyga, Octagam Immune Globulin (Human) |
| Amgen INC. | $421.26 | 2021-2025 | Tezspire, Actimmune |
| Blueprint Medicines Corporation | $417.20 | 2022-2025 | Ayvakit |
| Kaleo, INC. | $356.59 | 2021-2024 | Auvi-Q |
Show all 44 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biocryst US Sales Co., LLC | $342.37 | 2021-2025 | Orladeyo |
| Pharming Healthcare, INC. | $326.17 | 2019-2025 | Ruconest |
| Abbvie INC. | $301.71 | 2022-2025 | Rinvoq |
| Incyte Corporation | $298.58 | 2021-2025 | Opzelura |
| Adma Biomanufacturing LLC | $256.93 | 2022-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $215.52 | 2019-2022 | |
| Shire North American Group INC | $189.72 | 2019 | |
| Galderma Laboratories, L.P. | $170.47 | 2025 | Nemluvio |
| Gc Biopharma USA, INC. | $109.70 | 2024-2025 | Alyglo, Alyglo |
| Teva Pharmaceuticals USA, INC. | $95.49 | 2019-2021 | |
| Leo Pharma INC. | $92.66 | 2022-2023 | Adbry |
| Horizon Therapeutics Plc | $87.76 | 2019-2022 | |
| Sanofi-Aventis U.S. LLC | $84.21 | 2019-2022 | |
| Ars Pharmaceuticals Operations, INC. | $68.06 | 2025 | Neffy |
| Organon LLC | $67.35 | 2025 | Vtama |
| Lilly USA, LLC | $67.12 | 2025 | Ebglyss, Taltz |
| Covis Pharma Gmbh | $66.46 | 2021 | |
| Kedrion Biopharma, INC. | $56.35 | 2024 | Rhogam Ultra-Filtered Plus, Albuked, Koate |
| Stryker Corporation | $38.93 | 2024 | Clarifix Cryotherapy Device |
| Cycle Pharmaceuticals INC | $37.05 | 2024-2025 | Sajazir |
| Aimmune Therapeutics, INC. | $32.44 | 2021-2022 | |
| Bio Products Laboratory USA, INC. | $26.42 | 2022 | |
| Sunovion Pharmaceuticals INC. | $22.10 | 2020 | |
| Tersera Therapeutics LLC | $18.91 | 2025 | Quzyttir |
| Hikma Pharmaceuticals USA | $18.07 | 2023 | Ryaltris |
| Ionis Pharmaceuticals, INC. | $17.66 | 2025 | Dawnzera |
| Dermavant Sciences, INC. | $17.61 | 2024 | Vtama |
| Phadia US INC. | $15.87 | 2023 | Immunocap |
| Eyevance Pharmaceuticals LLC | $13.38 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ryan Casper listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.